Streetbeat News

STSA

Satsuma Pharmaceuticals Inc

satsumarx.com

CEO

John Kollins

Employees

Industry

Pharmaceutical Preparation Manufacturing

satsuma pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Insiders at Satsuma Pharmaceuticals, Erasca, and Aprea Therapeutics have been aggressively buying shares, indicating confidence in their respective companies. Satsuma Pharmaceuticals recently announced FDA acceptance of its STS101 migraine treatment, while Erasca discontinued its ERAS-007 programs, and Aprea Therapeutics posted a narrower quarterly loss.

Portfolio Pulse from Lisa Levin

June 09, 2023 | 11:30 am

Satsuma Pharmaceuticals' 505(b)(2) NDA for STS101, a novel migraine treatment, has been accepted for review by the FDA. Satsuma is in the process of being acquired by Shin Nippon Biomedical Laboratories, with a tender offer expiring on June 5, 2023.

Portfolio Pulse from Happy Mohamed

May 18, 2023 | 8:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.